Recent reports of Nipah virus infections in West Bengal, India, have prompted global public health authorities to prioritize research into this high-mortality pathogen. Sino Biological has announced the accelerated availability and development of critical research tools to support the global scientific community in combating Nipah virus.
Nipah virus, a member of the Paramyxoviridae family, is classified by the World Health Organization as a priority pathogen due to its epidemic potential and high fatality rate, estimated between 40% to 75%. With no approved vaccines or specific antiviral treatments currently available, the demand for high-quality, biologically active reagents is critical for developing effective countermeasures.
To meet the urgent needs of researchers, Sino Biological has launched a series of high-purity NiV G and F proteins. These proteins are essential for understanding viral entry mechanisms and screening therapeutic antibodies. Additionally, the company is fast-tracking the development of NiV N proteins and pre-fusion and post-fusion F trimer proteins. The N proteins are based on the most recently reported strains, offering improved sequence relevance compared with existing products that contain multiple mutations.
In addition to standard proteins, Sino Biological offers ProPure™ endotoxin-free versions of NiV G and F proteins, designed for vaccine research applications where immunogen purity and endotoxin control are critical. Researchers can access detailed information about these reagents through the company's dedicated Nipah virus research portal and specific product pages like the NiV proteins reagent section.
"Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when emerging infectious diseases threaten global health," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "By expanding our NiV portfolio, we aim to empower researchers to streamline vaccine discovery and diagnostic breakthroughs."
The company's comprehensive approach to supporting Nipah virus research comes at a critical time when global health organizations are seeking to develop effective countermeasures against this dangerous pathogen. The availability of these research tools could significantly accelerate the timeline for vaccine and diagnostic development, potentially saving lives during future outbreaks. For Texas-based biotech and pharmaceutical companies engaged in infectious disease research, this development represents an important advancement in research infrastructure that could facilitate collaborative efforts and accelerate local innovation in pandemic preparedness.
